| Filed On | Filing |
|---|---|
| 13 Nov 2026 | SCHEDULE 13G/A |
| 09 Nov 2026 | 10-Q |
| 09 Nov 2026 |
8-K: Results of Operations and Financial Condition
Phase 3 C-BEYOND Trial Achieved Primary and Secondary Endpoints, Reinforcing Potential Best-in-Class Profile of BEM/RZR for Treatment of Hepatitis C Virus (HCV) Infection |
| 09 Nov 2026 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation
CERTAIN INFORMATION MARKED AS [* * *] HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE COMPANY TREATS AS PRIVATE OR CONFIDENTIAL. |
| 06 Oct 2026 | SCHEDULE 13G |
| 12 Aug 2026 | 10-Q |
| 12 Aug 2026 |
8-K: Results of Operations and Financial Condition
Phase 3 C-BEYOND Trial Met Primary and Secondary Endpoints, with a Short 8-week Duration for Patients Without Cirrhosis Supporting a Potential Best-in-Class Profile of BEM/RZR for Treatment of HCV |
| 23 Jun 2026 |
Form 4: Lucidi Bruno, Director
Received 29,600 shares by exercise or conversion · Granted 26,700 Restricted Stock Units · Granted 37,700 Stock Option (Right to Buy) |
| 23 Jun 2026 |
Form 4: Berger Franklin M, Director
Received 29,600 shares by exercise or conversion · Granted 26,700 Restricted Stock Units · Granted 37,700 Stock Option (Right to Buy) |
| 23 Jun 2026 |
Form 4: Berman Howard, Director
Granted 26,700 Restricted Stock Units · Granted 37,700 Stock Option (Right to Buy) |
| 23 Jun 2026 |
Form 4: Duncan Barbara Gayle, Director
Received 29,600 shares by exercise or conversion · Granted 26,700 Restricted Stock Units · Granted 37,700 Stock Option (Right to Buy) |
| 23 Jun 2026 |
Form 4: Polsky Bruce, Director
Received 29,600 shares by exercise or conversion · Granted 26,700 Restricted Stock Units · Granted 37,700 Stock Option (Right to Buy) |
| 23 Jun 2026 |
Form 4: Murphy Polly A., Director
Received 29,600 shares by exercise or conversion · Granted 26,700 Restricted Stock Units · Granted 37,700 Stock Option (Right to Buy) |
| 23 Jun 2026 |
Form 4: Adams Jerome M., Director
Received 29,600 shares by exercise or conversion · Granted 26,700 Restricted Stock Units · Granted 37,700 Stock Option (Right to Buy) |
| 23 Jun 2026 |
Form 4: Kirsch Arthur S, Director
Granted 26,700 Restricted Stock Units · Granted 37,700 Stock Option (Right to Buy) |
| 22 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On June 18, 2026, Atea Pharmaceuticals, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). Holders of a total of 59,742,819 shares of the Company’s common stock were present in person or represented... |
| 21 May 2026 |
Form 4/A: Murphy Polly A., Director
Bought 6,100 shares ($25.4K) |
| 20 May 2026 |
Form 4: Murphy Polly A., Director
Bought 6,100 shares ($25.4K) |
| 12 May 2026 | 10-Q |
| 12 May 2026 |
8-K: Results of Operations and Financial Condition
C-BEYOND Phase 3 North American Trial for Treatment of Hepatitis C Virus (HCV) Remains on |
Loading...